Cost-Effectiveness of Erlotinib versus Docetaxel for Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer in the United Kingdom

Abstract

This study was designed to assess the cost-effectiveness of erlotinib compared with docetaxel in the second-line management of advanced non-small-cell lung cancer (NSCLC) within the UK National Health Service (NHS). A health-state transition model, based on two randomized phase III studies of erlotinib or docetaxel versus best supportive care, was used to estimate total direct costs, quality-adjusted life years (QALYs) and the subsequent net monetary benefit. Erlotinib was associated with a reduction in total costs (£13 730 versus £13 956) and improved outcomes (total QALYs of 0.238 versus 0.206) compared with docetaxel. Sensitivity analyses demonstrated the robustness of this analysis. In summary, erlotinib appeared to generate similar overall survival, an increase in QALYs and a small reduction in total NHS costs compared with docetaxel, due to lower adverse event and drug administration costs. Consequently, from a health economics perspective for the treatment of relapsed stage III - IV NSCLC patients in the UK, erlotinib has advantages over docetaxel.

Keywords

Non-small-cell lung cancer Cost-effectiveness analysis Erlotinib Docetaxel

References

Cancer Research UK: Lung Cancer: UK Lung Cancer Incidence Statistics. London: Cancer Research UK, 2009(available at: http://info.cancerresearchuk.org/cancerstats/types/lung/incidence/).

Cancer Research UK: Lung Cancer: UK Lung Cancer Mortality Statistics. London: Cancer Research UK, 2009(available at: http://info.cancerresearchuk.org/cancerstats/types/lung/mortality/).

Sculier

Fry

: Malignant Tumors of the Lung: Evidence-based Management. New York: Springer, 2004.

Hollen

Gralla

Kris

: Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer 1999; 7: 140–148.

Filderman

Shaw

Matthay

: Lung cancer. Part I: Etiology, pathology, natural history, manifestations, and diagnostic techniques. Invest Radiol 1986; 21: 80–90.

Schiller

Harrington

Belani

: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–98.

Shepherd

Dancey

Ramlau

: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.

Dancey

Shepherd

Gralla

: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: Results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183–194.

Fossella

DeVore

Kerr

: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18: 2354–2362.

10.

Hanna

Shepherd

Fossella

: Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–1597.

11.

Wailoo

Sutton

Morgan

: The risk of febrile neutopenia in patients with non-small-cell lung cancer treated with docetaxel: A systematic review and meta-analysis. Br J Cancer 2009; 100: 436–441.

12.

Kuderer

Dale

Crawford

: Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258–2266.

13.

Moyer

Barbacci

Iwata

: Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 1997; 57: 4838–4848.

14.

Salomon

Brandt

Ciardiello

: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183–232.

15.

Arteaga

: Targeting HER1/EGFR: A molecular approach to cancer therapy. Semin Oncol 2003; 30 (3 suppl 7): 3–14.

16.

Giaccone

: HER1/EGFR-targeted agents: Predicting the future for patients with unpredictable outcomes to therapy. Ann Oncol 2005; 16: 538–548.

17.

Shepherd

Pereira

J Rodrigues

Ciuleanu

: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353: 123–132.

18.

Ramalingam

Sandler

: Salvage therapy for advanced non-small cell lung cancer: Factors influencing treatment selection. Oncologist 2006; 11: 655–665.

19.

Kim

Hirsh

Mok

: Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): A randomised phase III trial. Lancet 2008; 372: 1809–1818.

20.

Bezjak

Seymour

: Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831–3837.

21.

Lynch

Jr Kim

Eaby

: Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007; 12: 610–621.

22.

Holmes

Dunlop

Hemmett

: A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer. Pharmacoeconomics 2004; 22: 581–594.

23.

National Institute for Health and Clinical Excellence (NICE): Docetaxel, Paclitaxel, Gemcitabine and Vinorelbine for the Treatment of Non-small Cell Lung Cancer. NICE Technology Appraisal 26. London: NICE, 2001(available at: http://www.nice.org.uk/TA26). Updated and incorporated into NICE Clinical Guideline 24 (available at http://www.nice.org.uk/nicemedia/pdf/cg024fullguideline.pdf).

24.

National Institute for Health and Clinical Excellence (NICE): Erlotinib for the Treatment of Non-small Cell Lung Cancer. NICE Technology Appraisal 162. London: NICE, 2008(available at: http://www.nice.org.uk/Guidance/TA162).

25.

Hawkins

Scott

Woods

: No study left behind: A network meta-analysis in non-small cell lung cancer demonstrating the importance of considering all relevant data. Value Health 2009; 12: 996–1003.

26.

National Institute for Health and Clinical Excellence (NICE): Guide to the Methods of Technology Appraisal. London: NICE, 2008(available at: http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf).

27.

Eli Lilly and Company: Pemetrexed in the Treatment of Non-small-cell Lung Cancer. Single Technology Appraisal (STA) Submission to the National Institute for Health and Clinical Excellence. Basingstoke: Eli Lilly and Company, 2006(available at: http://www.nice.org.uk/nicemedia/pdf/Lungcancer_pemetrexed_mansub.pdf).

28.

Rabin

de Charro

: EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001; 33: 337–343.

29.

Tabberer

Stamuli

Walker

: Utilities associated with non-small cell lung cancer (NSCLC): A community study. Value Health 2006; 9: A298 (abstract PCN74).

30.

National Institute for Health and Clinical Excellence (NICE): Briefing Paper for Methods Review Workshop on Key Issues in Utility Measurement. London: NICE, 2007(available at http://www.nice.org.uk/media/4A6/59/UtilitiesBriefingPaper010607KT.pdf).

31.

Parkin

Devlin

: Is there a case for using visual analogue scale valuations in cost-utility analysis? Health Econ 2006 15: 653–664.

32.

National Institute for Health and Clinical Excellence (NICE): Final Appraisal Determination: Erlotinib for the Treatment of Non-small-cell Lung Cancer. London: NICE, 2008(available at: http://www.nice.org.uk/nicemedia/pdf/ErlotinibFAD3220908.pdf).

33.

Personal Social Services Research Unit Hospital and Community Health Services (PSSRU): Unit Costs of Health and Social Care 2008: Inflation Indices. London: PSSRU, 2008 (available at: http://www.pssru.ac.uk/pdf/uc/uc2008/uc2008_inflationindices.pdf.

34.

British Medical Association and the Royal Pharmaceutical Society of Great Britain: British National Formulary 51. London: Pharmaceutical Press, 2006.

35.

Devlin

Parkin

: Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ 2004; 13: 437–452.

36.

Summerhayes

: The impact of workload changes and staff availability on IV chemotherapy services. J Oncol Pharm Pract 2003; 9: 123–128.

37.

Pompen

Novak

Postmus

: Pharmacoeconomic (PE) analysis of the treatment of non-small cell lung cancer (NSCLC) in The Netherlands demonstrates that erlotinib dominates docetaxel and is cost-effective over best supportive care (BSC) without need for patient stratification. Value Health 2006; 9: A203 (abstract CN3).

38.

Orlewska

Szczęsna

Gyldmark

: Cost effectiveness of erlotinib in the treatment of advanced non small cell lung cancer (NSCLC) in Poland. Value Health 2006; 9: A279 (abstract PCN12).

39.

Terres

C Rubio

Álvarez

Sanz C

Gylmark

GM Marlene

: Pharmacoeconomic analysis of therapy with erlotinib, docetaxel, pemetrexed or best supportive care in patients with advanced non-small cell lung cancer who have failed previous chemotherapy regimens. Value Health 2006; 9: A283–A284 (abstract PCN26).

40.

Kotowa

Gatzemeier

Pirk

: A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective. J Med Econ 2007; 10: 255–271.

41.

Ramsey

Clarke

Kamath

: Evaluation of erlotinib in advanced non-small cell lung cancer: Impact on the budget of a US health insurance plan. J Manag Care Pharm 2006; 12: 472–478.